Institutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$25m market cap decline as longer-term profits stay in the green [Yahoo! Finance]
Pyxis Oncology, Inc. (PYXS)
Company Research
Source: Yahoo! Finance
The top 10 shareholders own 50% of the company Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock If you want to know who really controls Pyxis Oncology, Inc. ( NASDAQ:PYXS ), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with 35% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company. No shareholder likes losing money on their investments, especially institutional investors who saw their holdings drop 11% in value last week. However, the 20% one-year return to shareholders may have helped lessen their pain. But they would probably be wary of future losses. Let's take a closer look to see what the different types of shareholders can tell us about Pyxis Oncology. Check out our latest analysis for Pyxis Oncology What Does The Institutional Ownership Tell Us About Pyxis
Show less
Read more
Impact Snapshot
Event Time:
PYXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PYXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PYXS alerts
High impacting Pyxis Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
PYXS
News
- Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Pyxis Oncology Expands Board of Directors with Appointment of Michael A. MetzgerGlobeNewswire
- Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare ConferenceGlobeNewswire
- Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024 [Yahoo! Finance]Yahoo! Finance
PYXS
Earnings
- 5/14/24 - Beat
PYXS
Sec Filings
- 6/12/24 - Form 8-K
- 6/10/24 - Form 4
- 6/10/24 - Form 3
- PYXS's page on the SEC website